文献速递脑血管病外科

如何提高大体积动静脉畸形分期体积立体定向放射外科的闭塞率

How to improve obliteration rates during volume-staged stereotactic radiosurgery for large arteriovenous malformations.
PubMed 文献 · J Neurosurg · 2018-07-20

作者回顾性检验通过增加接受最低阈值辐射剂量的动静脉畸形体积百分比可提高闭塞率的假设。1992年起对>15 cm3的动静脉畸形分期解剖组件以给予更高单次剂量,60例大动静脉畸形患者接受分期体积立体定向放射外科。结论认为处方边缘剂量≥17 Gy并使≥63%的内部剂量接受>20 Gy可改善结局。

要点

  • 60例大动静脉畸形接受分期体积立体定向放射外科,中位随访82个月。
  • 血管造影确认闭塞率3年4%、4年13%、5年23%、10年27%。
  • 边缘剂量≥17 Gy且20 Gy覆盖≥63%靶体积时,5年闭塞率61%、10年70%。

核心结论

  • 大动静脉畸形前瞻性分期体积立体定向放射外科的结局可通过处方动静脉畸形边缘剂量≥17 Gy并增加等中心使≥63%的内部动静脉畸形剂量接受>20 Gy来改善。

研究设计与样本

  • 作者于1992年前瞻性开始对体积>15 cm3的动静脉畸形分期解剖组件以给予更高单次剂量,此后60例大动静脉畸形患者接受了分期体积立体定向放射外科。
  • 回顾性检验通过增加接受最低阈值辐射剂量的动静脉畸形体积百分比可提高闭塞率的假设。
  • 第一次与第二次分期之间的中位间隔为4.5个月(2.8-13.8个月)。
  • 第一次分期立体定向放射外科的中位靶体积为11.6 cm3(范围4.3-26 cm3),第二次分期为10.6 cm3(范围2.8-33.7 cm3)。
  • 两个立体定向放射外科分期的中位边缘剂量均为16 Gy(范围13-18 Gy)。

主要发现

  • 初始两次分期体积立体定向放射外科治疗后,4例患者仅经MRI确认动静脉畸形闭塞,11例经血管造影确认,中位随访82个月(范围0.4-206个月)。
  • 分期体积立体定向放射外科后血管造影闭塞率3年为4%、4年为13%、5年为23%、10年为27%。
  • 多变量分析中,仅≥20 Gy体积覆盖与血管造影确认的更高总闭塞率显著相关。
  • 当边缘剂量≥17 Gy且20 Gy立体定向放射外科体积覆盖≥63%总靶体积时,血管造影确认的闭塞率5年增至61%、10年增至70%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The management of large-volume arteriovenous malformations (AVMs) with stereotactic radiosurgery (SRS) remains challenging. The authors retrospectively tested the hypothesis that AVM obliteration rates can be improved by increasing the percentage volume of an AVM that receives a minimal threshold dose of radiation. METHODS: In 1992, the authors prospectively began to stage anatomical components in order to deliver higher single doses to AVMs > 15 cm3 in volume. Since that time 60 patients with large AVMs have undergone volume-staged SRS (VS-SRS). The median interval between the first stage and the second stage was 4.5 months (2.8-13.8 months). The median target volume was 11.6 cm3 (range 4.3-26 cm3) in the first-stage SRS and 10.6 cm3 (range 2.8-33.7 cm3) in the second-stage SRS. The median margin dose was 16 Gy (range 13-18 Gy) for both SRS stages. RESULTS: AVM obliteration after the initial two staged volumetric SRS treatments was confirmed by MRI alone in 4 patients and by angiography in 11 patients at a median follow-up of 82 months (range 0.4-206 months) after VS-SRS. The post-VS-SRS obliteration rates on angiography were 4% at 3 years, 13% at 4 years, 23% at 5 years, and 27% at 10 years. In multivariate analysis, only ≥ 20-Gy volume coverage was significantly associated with higher total obliteration rates confirmed by angiography. When the margin dose is ≥ 17 Gy and the 20-Gy SRS volume included ≥ 63% of the total target volume, the angiographically confirmed obliteration rates increased to 61% at 5 years and 70% at 10 years. CONCLUSIONS: The outcomes of prospective VS-SRS for large AVMs can be improved by prescribing an AVM margin dose of ≥ 17 Gy and adding additional isocenters so that ≥ 63% of the internal AVM dose receives more than 20 Gy.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kano H, Flickinger JC, Nakamura A, et al. How to improve obliteration rates during volume-staged stereotactic radiosurgery for large arteriovenous malformations. J Neurosurg. 2018. PMID: 30028266. doi:10.3171/2018.2.JNS172964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。